Systematic review: The pathophysiology and management of polycystic liver disease

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 7, 2011, Pages 702-713

  Temmerman, F ^a   Missiaen, L ^b   Bammens, B ^c   Laleman, W ^a   Cassiman, D ^a   Verslype, C ^a   Van Pelt, J ^a   Nevens, F ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CALCIUM ION; CYCLIC AMP; EVEROLIMUS; HEPATOCYSTIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PLACEBO; POLYCYSTIN 1; POLYCYSTIN 2; PROTEIN KINASE C; RAPAMYCIN; SOMATOMEDIN C; TOLVAPTAN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASOPRESSIN RECEPTOR ANTAGONIST;

ABDOMINAL CRAMP; APOPTOSIS; ASPIRATION SCLEROTHERAPY; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CELL PROLIFERATION; CHOLANGIOCYTE; CLINICAL FEATURE; CYST ASPIRATION; DIAGNOSTIC IMAGING; ENDOPLASMIC RETICULUM; FENESTRATION; GENE; GENE MUTATION; GENE OVEREXPRESSION; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; INTRACELLULAR SIGNALING; INTRACRANIAL ANEURYSM; INTRAHEPATIC BILE DUCT; KIDNEY POLYCYSTIC DISEASE; LABORATORY DIAGNOSIS; LIVER CELL; LIVER POLYCYSTIC DISEASE; LIVER RESECTION; LIVER TRANSPLANTATION; LIVER WEIGHT; LOSS OF FUNCTION MUTATION; MALNUTRITION; NONHUMAN; PARTIAL LIVER RESECTION; PKD1 GENE; PKD2 GENE; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; PUBERTY; REVIEW; SCLEROTHERAPY; SCREENING; STEATORRHEA; SYSTEMATIC REVIEW; TREATMENT INDICATION;

ANIMALS; CYSTS; GENE EXPRESSION REGULATION; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052504971     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04783.x     Document Type: Review

References (98)

1. Hoevenaren IA, Wester R, Schrier RW, et al. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int 2008; 28: 264-70. (Pubitemid 351201040)
2. Pirenne J, Aerts R, Yoong K, et al. Liver transplantation for polycystic liver disease. Liver Transpl 2001; 7: 238-45. (Pubitemid 32243820)
3. Russel RT, Pinson CW,. Surgical management of polycystic liver disease. World J Gastroenterol 2007; 13: 5052-9. (Pubitemid 47527340)
4. Katsuyama M, Masuyama T, Komura I, Hibino T, Takahashi H,. Characterization of a novel polycystic kidney rat model with accompanying polycystic liver. Exp Anim 2000; 49: 51-5.
5. Lager DJ, Qian Q, Bengal RJ, Ishibashi M, Torres VE,. The PCK rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 2001; 59: 126-36. (Pubitemid 32055221)
6. Gong AY, Tietz PS, Muff MA, et al. Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. Am J Physiol 2003; 284: C1205-14. (Pubitemid 36457401)
7. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF,. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology 2007; 132: 1104-16. (Pubitemid 46440866)
8. Masyuk TV, Masyuk AI, LaRusso N,. Cholangiociliopathies: genetics, molecular mechanisms and potential therapies. Curr Opin Gastroenterol 2009; 25: 265-71.
9. Banales JM, Masyuk TV, Bogert PS, et al. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol 2008; 173: 1637-46.
10. van Keimpema L, Nevens F, Vanslembrouck R, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 137: 1661-8.
11. Hogan M, Tetyana V, Page L, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21: 1052-61.
12. Drenth J, Te Morsche R, Smink R, Bonifacino JS, Jansen JB,. Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat Genet 2003; 33: 345-7. (Pubitemid 36278850)
13. Davila S, Furu L, Gharavi AG, et al. Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet 2004; 36: 575-7. (Pubitemid 38715981)
14. Everson GT, Taylor MR, Doctor RB,. Polycystic disease of the liver. Hepatology 2004; 40: 774-82. (Pubitemid 39288107)
15. Waanders E, Venselaar H, Te Morsche RH, et al. Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63. Clin Genet 2010; 78: 47-56.
16. Torres VE, Harris PC,. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009; 76: 149-68.
17. Ong AC, Harris PC,. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int 2005; 67: 1234-47. (Pubitemid 40463100)
18. Kottgen M,. TRPP2 and autosomal dominant polycystic kidney disease. Biochim Biophys Acta 2007; 1772: 836-50. (Pubitemid 47179879)
19. Torres VE, Harris PC, Pirson Y,. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-301. (Pubitemid 46552051)
20. Qian F, Watnick TJ, Onuchic LF, Germino GG,. The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 1996; 87: 979-87. (Pubitemid 26427982)
21. Watnick T, Torres V, Gandolph M, et al. Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease. Mol Cell 1998; 2: 247-51. (Pubitemid 128373650)
22. Watnick T, He N, Wang K, et al. Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations. Nat Genet 2000; 25: 143-4. (Pubitemid 30394981)
23. Boletta A,. Emerging evidence of a link between the polycystins and the mTOR pathways. Pathogenetics 2009; 2: 6.
24. Desmet VJ,. Ludwig symposium on biliary disorders-part I. Pathogenesis of ductal plate abnormalities. Mayo Clin Proc 1998; 3: 80-9.
25. Ramos A, Torres VE, Holley K, Offord KP, Rakela J, Ludwig J,. The liver in autosomal dominant polycystic kidney disease. Implications for pathogenesis. Arch Pathol Lab Med 1990; 114: 180-4. (Pubitemid 20100713)
26. Qian Q, Li A, King BF, et al. Clinical profile of autosomal dominant polycystic liver disease. Hepatology 2003; 37: 164-71. (Pubitemid 36042157)
27. Lazaridis KN, Strazzabosco M, Larusso N,. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004; 127: 1565-77. (Pubitemid 39457780)
28. Everson GT, Emmett M, Brown WR, Redmond P, Thickman D,. Functional similarities of hepatic cystic and biliary epithelium: studies of fluid constituents and in vivo secretion in response to secretin. Hepatology 1990; 11: 557-65. (Pubitemid 20151731)
29. Perrone RD, Grubman SA, Rogers LC, et al. Continuous epithelial cell lines from ADPKD liver cysts exhibit characteristics of intrahepatic biliary epithelium. Am J Physiol 1995; 269: G335-45.
30. Perrone RD, Grubman SA, Murray SL, Lee DW, Alper SL, Jefferson DM,. Autosomal dominant polycystic kidney disease decreases anion exchanger activity. Am J Physiol 1997; 272: C1748-56.
31. Nichols MT, Gidey E, Matzakos T, et al. Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. Hepatology 2004; 40: 836-46. (Pubitemid 39288116)
32. Wheatley DN,. Primary cilia in normal and pathological tissues. Pathobiology 1995; 63: 222-8.
33. Ong AC, Wheatley DN,. Polycystic kidney disease-the ciliary connection. Lancet 2003; 361: 774-6. (Pubitemid 36293635)
34. Praetorius HA, Spring KR,. A physiological view of the primary cilium. Annu Rev Physiol 2005; 67: 515-29. (Pubitemid 40404499)
35. Davenport JR, Yoder BK,. An incredible decade for the primary cilium: a look at a once-forgotten organelle. Am J Physiol 2005; 289: F1159-69. (Pubitemid 41681349)
36. Masyuk AI, Masyuk TV, LaRusso NF,. Cholangiocyte primary cilia in liver health and disease. Dev Dyn 2008; 237: 2007-12.
37. Alvaro D, Onori P, Alpini G, et al. Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney. Am J Pathol 2008; 172: 321-32. (Pubitemid 351282020)
38. Alvaro D, Mancino MG, Glaser S, et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 2007; 132: 415-31. (Pubitemid 46108729)
39. Alvaro D, Gigliozzi A, Attili AF,. Regulation and deregulation of cholangiocyte proliferation. J Hepatol 2000; 33: 333-40. (Pubitemid 30485240)
40. Waanders E, Van Krieken JH, Lameris AL, Drenth JP,. Disrupted cell adhesion but not proliferation mediates cyst formation in polycystic liver disease. Mod Pathol 2008; 21: 1293-302.
41. Murray SL, Grubman SA, Perrone RD, et al. Matrix metalloproteinase activity in human intrahepatic biliary epithelial cell lines from patients with autosomal dominant polycystic kidney disease. Connect Tissue Res 1996; 33: 249-56.
42. Fabris L, Cadamuro M, Fiorotto R, et al. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology 2006; 43: 1001-12. (Pubitemid 43724625)
43. Amura CR, Brodsky KS, Groff R, Gattone VH, Voelkel NF, Doctor RB,. VEGF receptor inhibition blocks liver cysts growth in pkd2(WS25/-) mice. Am J Physiol Cell Physiol 2007; 293: C419-28. (Pubitemid 47105041)
44. Harris RA, Gray DW, Britton BJ, Toogood GJ, Morris PJ,. Hepatic cystic disease in an adult polycystic kidney disease transplant population. Aust N Z J Surg 1996; 66: 166-8. (Pubitemid 126422985)
45. Sherstha R, McKinley C, Russ P, et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology 1997; 26: 1282-6. (Pubitemid 27509314)
46. Alvaro D, Mancino MG, Onori P, et al. Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol 2006; 12: 3537-45. (Pubitemid 43997030)
47. Van Keimpema L, de Koning DB, van Hoek B, et al. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int 2011; 31: 92-8.
48. Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP,. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 2006; 17: 178-87.
49. Leuenroth SJ, Okuhara D, Shotwell JD,. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci USA 2007; 104: 4389-94. (Pubitemid 47186236)
50. Gao H, Wang Y, Wegierski T, et al. PRKCSH/80K-H, the protein mutated in polycystic liver disease, protects polycystin-2/TRPP2 against HERP-mediated degradation. Hum Mol Genet 2010; 19: 16-24.
51. Kawaai K, Hisatsune C, Kuroda Y, Mizutani A, Tashiro T, Mikoshiba K,. 80K-H interacts with inositol 1,4,5-trisphosphate (IP3) receptors and regulates IP3-induced calcium release activity. J Biol Chem 2009; 284: 372-80.
52. Shibao K, Hirata K, Robert ME, Nathanson MH,. Loss of inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis. Gastroenterology 2003; 125: 1175-87. (Pubitemid 37193463)
53. 2+)-, and protein kinase C alpha-dependent mechanisms. Hepatology 2000; 32: 17-25. (Pubitemid 30432361)
54. Yamaguchi T, Nagao S, Wallace DP, et al. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 2003; 63: 1983-94. (Pubitemid 36605809)
55. Banales JM, Masyuk TV, Gradilone SA, Masyuk AI, Medina JF, Larusso NF,. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology 2009; 49: 160-74.
56. Qian Q, Du H, King BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 2008; 19: 631-8. (Pubitemid 351355407)
57. Spirli C, Okolicsanyi S, Fiorotto R, et al. Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology 2010; 51: 1778-88.
58. Everson GT,. Hepatic cysts in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1993; 22: 520-5. (Pubitemid 23308960)
59. Bae KT, Zhu F, Chapman AB, et al. Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP): magnetic Resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 2006; 1: 64-9.
60. Caroli A, Antiga L, Cafaro M, et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010; 5: 783-9.
61. Drenth J, Chrispijn M, Nagorney D, Kamath PS, Torres VE,. Medical and surgical treatment options for polycystic liver disease. Hepatology 2010; 52: 2223-30.
62. Grantham J, Torres V, Chapman A, et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122-30. (Pubitemid 43736612)
63. Dmitrewski J, Olliff S, Buckels JA,. Obstructive jaundice associated with polycystic liver disease. HPB Surg 1996; 10: 117-20. (Pubitemid 26413973)
64. Abascal J, Moya M, Martin F,. Infection of hepatic cysts in polycystic disease. World J Surg 1984; 8: 424-5.
65. Schievink WI, Spetzler RF,. Screening for intracranial aneurysms in patients with isolated polycystic liver disease. J Neurosurg 1998; 89: 719-21. (Pubitemid 28485529)
66. Ong AC,. Screening for intracranial aneurysms in ADPKD. BMJ 2009; 339: b3763.
67. Lumiaho A, Ikäheimo R, Miettinen R, et al. Mitral valve prolaps and mitral regurgitation are common in patients with polycystic kidney disease type I. Am J Kidney Dis 2001; 38: 1208-16. (Pubitemid 34193105)
68. Levine E, Cook LT, Grantham JJ,. Liver cysts in autosomal-dominant polycystic kidney disease: clinical and computed tomographic study. Am J Roentgenol 1985; 145: 229-33. (Pubitemid 16239635)
69. Itai Y, Ebihara R, Eguchi N, et al. Hepatobiliary cysts in patients with autosomal dominant polycystic kidney disease: prevalence and CT findings. Am J Roentgenol 1995; 164: 339-42.
70. Nicolau C, Torra R, Bianchi L, et al. Abdominal sonographic study of autosomal dominant polycystic kidney disease. J Clin Ultrasound 2000; 28: 277-82. (Pubitemid 30436582)
71. Everson GT, Scherzinger A, Berger-Leff N, et al. Polycystic liver disease: quantitation of parenchymal and cyst volumes from computed tomography images and clinical correlates of hepatic cysts. Hepatology 1988; 8: 1627-34. (Pubitemid 19021899)
72. Waanders E, van Keimpema L, Brouwer JT, et al. Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease. Liver Int 2009; 29: 1389-95.
73. Xu HW, Yu SQ, Mei CL, Li MH,. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. Stroke 2011; 42: 204-6.
74. Qian Q,. Isolated polycystic liver disease. Adv Chronic Kidney Dis 2010; 17: 181-9.
75. Ecder T, Schrier RW,. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol 2009; 5: 221-8.
76. Gigot J-F, Hubert C, Banice R, Kendrick ML,. Laparoscopic management of benign liver diseases: where are we? HPB 2004; 6: 197-212. (Pubitemid 40124743)
77. Saini S, Mueller PR, Ferrucci JT Jr, Simeone JF, Wittenberg J, Butch RJ,. Percutaneous aspiration of hepatic cysts does not provide definitive therapy. Am J Roentgenol 1983; 141: 559-60. (Pubitemid 13039911)
78. Bean WJ, Rodan BA,. Hepatic cysts: treatment with alcohol. Am J Roentgenol 1985; 1: 237-41. (Pubitemid 15168317)
79. van Keimpema L, Ruurda JP, Ernst MF, van Geffen HJ, Drenth JP,. Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%. J Gastrointest Surg 2008; 12: 477-82.
80. Armitage NC, Blumgart LH,. Partial resection and fenestration in the treatment of polycystic liver disease. Br J Surg 1984; 71: 242-4. (Pubitemid 14195522)
81. Schindl MJ, Redhead DN, Fearon KC, Garden OJ, Wigmore SJ,. The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection. Gut 2005; 54: 289-96. (Pubitemid 40139248)
82. Available at:.
83. Stickel F, Inderbitzin D, Candinas D,. Role of nutrition in liver transplantation for end-stage chronic liver disease. Nutr Rev 2008; 66: 47-54. (Pubitemid 351666661)
84. Freeman RB Jr, Gish RG, Harper A, et al. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2006; 12: S128-36. (Pubitemid 44911794)
85. Arrazola L, Moonka D, Gish RG, Everson GT,. Model for end-stage liver disease (MELD) exception for polycystic liver disease. Liver Transpl 2006; 12: S110-1. (Pubitemid 44911786)
86. Rasmussen A, Davies HF, Jamieson NV, Evans DB, Calne RY,. Combined transplantation of liver and kidney from the same donor protects the kidney from rejection and improves kidney graft survival. Transplantation 1995; 59: 919-21.
87. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M,. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol 2008; 68: 473-80. (Pubitemid 351257869)
88. Chrispijn M, van Keimpema L, Nevens F, et al. Growth of liver volume stops after one year of lanreotide in patients with polycystic livers. J Hepatol 2010; 52 (Suppl. 1): S31-3.
89. Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 820-9.
90. Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 830-40.
91. Watnick T, Germino GG,. mTOR inhibitors in polycystic kidney disease. N Engl J Med 2010; 363: 879-81.
92. Renken C, Fischer DC, Kundt G, Gretz N, Haffner D,. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats. Nephrol Dial Transplant 2011; 26: 92-100.
93. Gattone VH, Wang X, Harris PC, Torres VE,. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9: 1323-6. (Pubitemid 37279858)
94. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH,. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10: 363-4. (Pubitemid 38508512)
95. Wang X, Gattone V, Harris PC, Torres VE,. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005; 16: 846-51. (Pubitemid 41710293)
96. Torres VE,. Treatment strategies and clinical trial design in ADPKD. Adv Chronic Kidney Dis 2010; 17: 190-204.
97. Torres VE, Meijer E, Bae KT, et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis 2011; 57: 692-9.
98. Irazabal MV, Torres VE, Hogan MC, et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 2011; 80: 295-301.